A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: f
View:
• Able to understand the procedures of this trial and provide written informed consent voluntarily;
• Age between 18 to 55 years, male or female;
• ADPKD diagnostic criteria were met before randomization;
• Rapidly progressive ADPKD criteria were met.
Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
xiaojun zhou
zhouxiaojun@jemincare.com
+8613717736760
Time Frame
Start Date: 2025-03-13
Estimated Completion Date: 2027-05-30
Participants
Target number of participants: 135
Treatments
Experimental: JMKX003142
Placebo_comparator: placebo
Related Therapeutic Areas
Sponsors
Leads: Jemincare